AstraZeneca shares slide 7% as investors and analysts pan reported Bristol Myers merger talks

The market's verdict

AstraZeneca shares tumbled in London on Monday, falling as much as 8.8% before paring losses to roughly 7%, wiping nearly £15 billion off its market capitalisation. The sell-off followed a Financial Times report that the company had held preliminary merger talks with US-based Bristol Myers Squibb. A person familiar with the matter confirmed the discussions to Reuters, while cautioning that any deal could still be delayed or collapse. Neither AstraZeneca nor BMS has commented publicly.

The combined entity would rank as the world's fourth-largest drugmaker by market capitalisation, approaching $400 billion. As of Friday's close, AstraZeneca was valued at $264.11 billion and Bristol Myers at $133.41 billion, according to Reuters data. The talks remain at an early stage and the exact terms under discussion could not be confirmed.

Investor pushback

Shareholders reacted with open scepticism. Markus Manns, a portfolio manager at Union Investment and a holder of both stocks, said the deal "makes neither strategic nor financial sense" and called on the companies to abandon the talks.

Many of the mega-mergers of the past have destroyed value, while the R&D performance of the companies involved took years to recover from the 'merger shocks'.

Evangelos Assimakos, senior investment director at Rathbones, a top-30 AstraZeneca shareholder, described the potential tie-up as a "surprise" given the company's existing growth trajectory. AstraZeneca generated revenues of $58.7 billion last year and is targeting $80 billion by 2030. Assimakos also flagged antitrust risk, noting that the significant overlap in cancer and cardiovascular medicines could require "significant divestments."

The patent cliff problem

A central objection is that AstraZeneca would be acquiring a company facing a steep patent cliff. Bristol Myers' blockbuster cancer drug Opdivo is among the products whose sales are expected to plunge as patents expire between now and 2030. The US group stands to lose almost half its revenues over the coming years, according to the Financial Times. Investors questioned why AstraZeneca would volunteer to absorb that exposure when its own pipeline is robust.

AstraZeneca is awaiting clinical data on new drugs targeting various cancers, obesity, and respiratory conditions such as asthma. Chief executive Sir Pascal Soriot told reporters as recently as last month that he did not "need M&A to deliver" on the 2030 revenue target. The company's existing strategy of supplementing internal development with licensing deals and partnerships, particularly in China, has been a proven formula.

Soriot's legacy and the Pfizer echo

Soriot, 67, has led AstraZeneca since 2012. His tenure was defined early by the successful defence against a near-£70 billion hostile takeover bid from Pfizer in 2014, a victory he turned into a rallying cry for a turnaround. Since then, AstraZeneca's market value has roughly tripled, reaching as high as £200 billion at points. The $39 billion acquisition of Alexion in 2021 expanded the company into rare-disease medicines, a move viewed as consistent with Soriot's science-led philosophy.

A mega-merger with Bristol Myers would mark a sharp departure. Analysts at Jefferies commented that if any company does not need financial engineering, it is AstraZeneca. The Guardian noted that Soriot risks spoiling his legacy if a high-risk financial adventure goes wrong, while the Frankfurter Allgemeine questioned why he would burden himself with years of integration effort when organic growth is delivering.

Regulatory and political hurdles

Antitrust regulators in the United States would likely scrutinise a combination of two leading oncology franchises. Both companies market rival medicines to Merck's Keytruda, AstraZeneca's Imfinzi and Bristol Myers' Opdivo, creating direct competitive overlap. The Frankfurter Allgemeine reported that AstraZeneca would probably have to sell off business units to secure approval.

In London, the government may also raise concerns. A merger with a US rival could increase the temptation for AstraZeneca to shift its primary listing to New York, a loss the London Stock Exchange would find hard to absorb given the company's status as its second-most-valuable constituent. The combination of investor hostility, regulatory complexity, and political sensitivity suggests the talks may quietly end, as several outlets speculated on Monday.